Can I read Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM). on EtoBox?

Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM). by Stakiw, Julie; Kukreti, Vishal; LeBlanc, Richard; Sebag, Michael; Hay, Annette; Cote, Julie; Camacho, Fernando; Gul, Engin; Reece, Donna is a Medicine article available to read on EtoBox.

What is Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM). about?

thrombocytopenia (7%) and infectious disease (5%). Conclusion: Pomalidomide-based therapy demonstrates efficacy in the real life with a manageable safety profile. Further study ill look into triplet versus doublet pomalidomide-based regimen, with a benefit expected for the former. Further prospective studies are warranted to confirm this data on a larger MM population.

Who reads Initial Results of MCRN 009: Phase 2 Study of an Accelerated Infusion Rate of Daratumumab in Patients with Relapsed/Refractory Multiple Myeloma (MM).?

Author

Stakiw, Julie; Kukreti, Vishal; LeBlanc, Richard; Sebag, Michael; Hay, Annette; Cote, Julie; Camacho, Fernando; Gul, Engin; Reece, Donna

Publisher

Elsevier ; Cancer Media Group; Elsevier BV (ISSN 2152-2650)

Published

2019

Language

EN

Field

Medicine (Health Sciences)